RT Journal Article
SR Electronic
T1 Characteristics of changes in circulating markers of alveolar epithelial and endothelial injury in acute respiratory distress syndrome with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.10.21249528
DO 10.1101/2021.01.10.21249528
A1 Tojo, Kentaro
A1 Yamamoto, Natsuhiro
A1 Mihara, Takahiro
A1 Abe, Miyou
A1 Goto, Takahisa
YR 2021
UL http://medrxiv.org/content/early/2021/01/11/2021.01.10.21249528.abstract
AB The time course and specific contributions of alveolar epithelial and endothelial injury to the pathogenesis of acute respiratory distress syndrome (ARDS) with coronavirus disease (COVID-19) remain unclear. Here, we evaluated the characteristics of circulating markers of alveolar epithelial and endothelial injury in 107 serum samples from nine ARDS patients and eight non-ARDS patients, all with COVID-19. Although both the alveolar epithelial and endothelial injury markers were markedly elevated in the COVID-19 ARDS patients, our data indicate that the endothelial injury, which continues for a longer period than the epithelial injury, seems to be the main contributor to alveolar barrier disruption.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Yokohama City University HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified patient data collected for the study will be rendered available by writing to KT (ktojo-cib@umin.net).